View More Recent Stories

Jan 18, 2023 03:01AM Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
Jan 18, 2023 03:01AM Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
Jan 3, 2023 05:58AM Mainz Biomed (MYNZ) Provides Year-End 2022 Update
Jan 3, 2023 03:01AM Mainz Biomed Provides Year-End 2022 Corporate Review
Jan 3, 2023 03:01AM Mainz Biomed Provides Year-End 2022 Corporate Review
Dec 20, 2022 03:01AM Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
Dec 20, 2022 03:01AM Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
Dec 6, 2022 03:01AM Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study
Dec 6, 2022 03:01AM Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study
Nov 29, 2022 08:00AM Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies
Nov 29, 2022 08:00AM Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies
Nov 22, 2022 08:00AM Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
Nov 22, 2022 08:00AM Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
Nov 15, 2022 08:00AM Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert
Nov 15, 2022 08:00AM Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert
Nov 2, 2022 08:00AM Mainz Biomed Provides Third Quarter 2022 Update
Nov 2, 2022 08:00AM Mainz Biomed Provides Third Quarter 2022 Update
View More Recent Stories